Equities

Nuformix PLC

NFX:LSE

Nuformix PLC

Health CarePharmaceuticals and Biotechnology
  • Price (GBX)0.185
  • Today's Change0.00 / 0.00%
  • Shares traded67.65k
  • 1 Year change-31.48%
  • Beta1.1319
Data delayed at least 20 minutes, as of May 17 2024 10:23 BST.
More ▼

Financials data is unavailable for this security.

Inc stmt in GBPIncome statement in GBPView more

Year on year Nuformix PLC had revenues fall -100.00% from 50.00k to 0.00, though the company grew net income from a loss of 1.11m to a smaller loss of 859.47k.
Gross margin--
Net profit margin--
Operating margin--
Return on assets-9.50%
Return on equity-9.95%
Return on investment-9.95%
More ▼

Cash flow in GBPView more

In 2023, cash reserves at Nuformix PLC fell by 261.55k. Cash Flow from Financing totalled 284.69k or -- of revenues. In addition the company used 596.23k for operations while cash from investing totalled 50.00k.
Cash flow per share-0.0006
Price/Cash flow per share--
Book value per share0.0056
Tangible book value per share0.0002
More ▼

Balance sheet in GBPView more

Nuformix PLC uses little or no debt in its capital structure.
Current ratio1.51
Quick ratio--
Total debt/total equity0.00
Total debt/total capital0.00
More ▼
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.